Hospira, Stada Arzneimittel AG, and Bioceuticals Arzneimittel AG, a Stada-initiated company focused on biosimilar products, have entered into a development, manufacturing and distribution agreements for a generic version of erythropoietin (EPO). Erythropoietin is a naturally occurring protein hormone produced by the kidney. Therapeutic erythropoietin is used to treat anemia in dialysis and in certain oncology applications. “Developing and providing access to biosimilars is a natural e...